This process strengthens antioxidant responses, ultimately preventing osteoclast development,[202] which shows that BACH1 might be worth considering as a therapeutic target for bone destruction diseases such as osteoporosis and rheumatoid arthritis (RA).[204, 205, 206, 207] BACH1 is crucial in bone metabolism by influencing osteoblasts and osteoclasts, highlighting the need for future development of skeletal system‐specific BACH1 inhibitors. This evidence concerns the gene BACH1 and rheumatoid arthritis.